ANRO · Alto Neuroscience, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| R&D | $20.29M | - | $10.53M | $13.12M | $9.97M | - | $13.06M | $7.07M | $9.95M |
| SG&A | $6.84M | - | $4.43M | $5.56M | $5.70M | - | $5.83M | $2.05M | $4.43M |
| Total Operating Expenses | $27.14M | - | $14.95M | $18.68M | $15.68M | - | $18.89M | $18.34M | $14.39M |
| D&A | $171.0K | - | $200.0K | $100.0K | $171.0K | - | $200.0K | $100.0K | $97.0K |
| Operating Income | ($27.14M) | - | ($14.95M) | ($18.68M) | ($15.68M) | - | ($18.89M) | ($9.13M) | ($14.39M) |
| Interest Expense | $545.0K | - | $650.0K | $646.0K | $598.0K | - | $349.0K | $327.0K | $346.0K |
| Income Tax | - | - | - | - | $0 | - | - | - | $0 |
| Net Income | ($26.24M) | - | ($14.18M) | ($17.71M) | ($15.17M) | - | ($16.78M) | ($16.03M) | ($13.42M) |
| EPS - Basic | ($0.80) | - | ($0.52) | ($0.65) | ($0.56) | - | ($0.62) | ($2.33) | ($0.76) |
| EPS - Diluted | ($0.80) | - | ($0.52) | ($0.65) | ($0.56) | - | ($0.62) | ($2.33) | ($0.76) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $263.76M | $176.48M | $137.82M | $147.59M | $160.75M | $168.23M | $181.70M | $193.12M | $205.90M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.37M | $1.88M | $2.06M | $1.67M | $1.38M | $1.58M | $2.25M | $1.84M | $2.41M |
| Current Assets | $269.13M | $177.72M | $139.45M | $149.85M | $163.52M | $169.34M | $183.53M | $195.41M | $85.39M |
| Total Assets | $276.26M | $184.69M | $147.01M | $157.88M | $171.91M | $177.54M | $191.61M | $197.36M | $209.92M |
| Current Liabilities | $13.12M | $11.32M | $9.04M | $8.13M | $7.26M | $10.01M | $14.02M | $9.84M | $8.01M |
| Long-term Debt | $13.88M | $16.17M | $20.31M | $20.12M | $19.94M | $10.25M | $6.63M | $7.74M | $8.81M |
| Total Liabilities | $32.89M | $33.55M | $35.45M | $34.47M | $32.82M | $26.08M | $26.56M | $17.58M | $16.82M |
| Stockholders' Equity | $243.37M | $151.14M | $111.56M | $123.41M | $139.10M | $151.46M | ($61.10M) | $179.78M | $193.10M |
| Retained Earnings | ($227.87M) | ($201.63M) | ($185.45M) | ($171.27M) | ($153.56M) | ($138.40M) | ($123.19M) | ($106.41M) | ($76.97M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($27.09M) | - | - | - | ($16.56M) | - | - | - | ($10.98M) |
| Investing Cash Flow | ($556.0K) | - | - | - | ($24.0K) | - | - | - | ($224.0K) |
| Financing Cash Flow | $114.94M | - | - | - | $9.13M | - | - | - | $134.56M |
| CapEx | $556.0K | - | - | - | $24.0K | - | - | - | $224.0K |
| Free Cash Flow | ($27.65M) | - | - | - | ($16.58M) | - | - | - | ($11.21M) |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross margin | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.05 | - | - | - | 1.09 | - | - | - | 0.84 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.5% | - | -9.6% | -11.2% | -8.8% | - | -8.8% | -8.1% | -6.4% |
| Return on equity | -10.8% | - | -12.7% | -14.3% | -10.9% | - | 27.5% | -8.9% | -6.9% |
| Return on invested capital | - | - | - | - | -7.8% | - | - | - | -5.6% |
| Liquidity | |||||||||
| Current ratio | 20.52 | 15.69 | 15.42 | 18.43 | 22.53 | 16.92 | 13.09 | 19.85 | 10.67 |
| Quick ratio | 20.52 | 15.69 | 15.42 | 18.43 | 22.53 | 16.92 | 13.09 | 19.85 | 10.67 |
| Cash ratio | 20.11 | 15.58 | 15.24 | 18.16 | 22.15 | 16.81 | 12.96 | 19.62 | 25.72 |
| Leverage | |||||||||
| Debt / Equity | 0.06 | 0.11 | 0.18 | 0.16 | 0.14 | 0.07 | -0.11 | 0.04 | 0.05 |
| Debt / Assets | 0.05 | 0.09 | 0.14 | 0.13 | 0.12 | 0.06 | 0.03 | 0.04 | 0.04 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest coverage | -49.8x | - | -23.0x | -28.9x | -26.2x | - | -54.1x | -27.9x | -41.6x |
| Equity multiplier | 1.14 | 1.22 | 1.32 | 1.28 | 1.24 | 1.17 | -3.14 | 1.10 | 1.09 |
| Liabilities / Assets | 0.12 | 0.18 | 0.24 | 0.22 | 0.19 | 0.15 | 0.14 | 0.09 | 0.08 |
| Efficiency | |||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - |
| Valuation | |||||||||
| P / E | - | - | - | - | - | - | - | - | - |
| P / B | 3.0x | - | 1.0x | 0.5x | 0.4x | - | - | 1.6x | 1.4x |
| P / S | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - |
| Growth | |||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -73.1% | - | 20.8% | -104.7% | -9.0% | - | - | - | - |
| Net income growth (YoY) | -73.0% | - | 15.5% | -10.5% | -13.1% | - | - | - | - |
| EPS growth (YoY) | -42.9% | - | 16.1% | 72.1% | 26.3% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -66.7% | - | - | - | -47.9% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 75.0% | -0.2% | - | -31.4% | -28.0% | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Alto Neuroscience against the 5 most active filers in the same SIC group.